VISIONARY-MS Blinded Interim Data Update

VISIONARY-MS STUDY

Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy for Assessment of Remyelination in Stable RMS

P113

H. Beadnall[1],A. Klistorner[3], M. Barnett[3], R. Sergott[4], A. Rynders[2], K.S. Ho[2], M. Mortenson[5], R. Glanzman[2], M. Hotchkin[2]

[1]Sydney Brain Mind Centre and Royal Prince Alfred Hospital, University of Sydney, Australia. [2]Clene Nanomedicine, Salt Lake City, UT. [3]Sydney Neuroimaging Analysis Centre, Sydney, Australia. [4]Annesley EyeBrain Center at Thomas Jefferson University Partnered with Wills Eye Hospital, Philadelphia, PA. [5]Clene Nanomedicine, North East, MD.

Best Corrected Low Contrast Letter Acuity (OD/OS)

Sloan 2.5% Contrast (2 meter)

Symbol Digit Modalities Test (Cognition)

9-Hole Peg Test (D/ND)

Timed 25-Foot Walk

LCLA (Primary Endpoint)

LCLA (All Eyes) Average Z-Score
14-February-2022 Data Cut, Preliminary Blinded Data
(vs. 'Mild' EDSS [≤1.5]; Mean ± SEM)



Eyes, n =	142	138	128	118	102

(m)MSFC Secondary Endpoint

(m)MSFC 6-Component Average Z-Score
14-February-2022 Data Cut, Preliminary Blinded Data
(vs. 'Mild' EDSS [≤1.5]; Mean ± SEM)



All Subjects with at least 4 of 6 (m)MSFC Domains by Completed Subject Visit. (m)MSFC domains include LCLA (OS/OD), 9HPT (D/ND), T25FW, SDMT.

n =	73	70	65	60	53

SDMT Average Z-Score (vs. Mild EDSS ≤1.5)
14-February-2022 Data Cut, Preliminary Blinded Data
(vs. 'Mild' EDSS [≤1.5]; Mean ± SEM)



n =	72	71	65	58	52

9HPT Dominant Average Z-Score
14-February-2022 Data Cut, Preliminary Blinded Data
(vs. 'Mild' EDSS [≤1.5]; Mean ± SEM)



n =	73	71	65	60	54

9HPT Non-Dominant Average Z-Score
14-February-2022 Data Cut, Preliminary Blinded Data
(vs. 'Mild' EDSS [≤1.5]; Mean ± SEM)



n =	73	71	65	60	54

T25FW Average Z-Score
14-February-2022 Data Cut, Preliminary Blinded Data
(vs. 'Mild' EDSS [≤1.5]; Mean ± SEM)



n =	72	69	62	57	53

- **Design:** Randomized Double-Blind Placebo Controlled Trial (1:1:1, 30mg, 15mg, Placebo)
- **Safety:** No treatment related SAEs, TEAEs predominantly mild-to-moderate and transient
- **Conclusion:** Blinded data show clinically relevant improvements across LCLA & modified-MSFC domains

Notes: Mixed Effects Model, Dunnett's test for multiplicity; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. Z-Score based on Baseline value for EDSS with 'Mild' Severity (e.g., BL Low EDSS [≤1.5]) for each domain. (m)MSFC is the modified MS Functional composite (Low contrast letter acuity (LCLA), 9-hole peg test (9HPT), Timed 25-foot walk (T25FW), and Symbol digit modalities test (SDMT)). All available data in EDC.

CLENE NANOMEDICINE